Answer
The safety and efficacy of atezolizumab (Tecentriq) have not been established in children and adolescents aged below 18 years, and no dosing recommendation can be made.
Sources for this answer
- Tecentriq 840 mg and 1,200 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 41Document updated
Sources checked